Debt-to-equity of Y-mAbs Therapeutics, Inc. from 30 Jun 2019 to 30 Jun 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Y-mAbs Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2019 to 30 Jun 2025.
  • Y-mAbs Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Jun 2025 was 30%, a 6.9% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Y-mAbs Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q2 2025 30% -2.2% -6.9% 30 Jun 2025
Q1 2025 35% +8.2% +31% 31 Mar 2025
Q4 2024 34% +6.8% +25% 31 Dec 2024
Q3 2024 33% +5% +18% 30 Sep 2024
Q2 2024 32% +3.2% +11% 30 Jun 2024
Q1 2024 27% -2.3% -8% 31 Mar 2024
Q4 2023 27% +0.5% +1.9% 31 Dec 2023
Q3 2023 28% +4.5% +19% 30 Sep 2023
Q2 2023 29% +10% +54% 30 Jun 2023
Q1 2023 29% +13% +87% 31 Mar 2023
Q4 2022 27% +14% +114% 31 Dec 2022
Q3 2022 24% +11% +84% 30 Sep 2022
Q2 2022 19% +4.8% +34% 30 Jun 2022
Q1 2022 15% -0.22% -1.4% 31 Mar 2022
Q4 2021 12% -4.6% -27% 31 Dec 2021
Q3 2021 13% -0.38% -2.9% 30 Sep 2021
Q2 2021 14% +1.8% +14% 30 Jun 2021
Q1 2021 16% +3% +24% 31 Mar 2021
Q4 2020 17% +4.1% +32% 31 Dec 2020
Q3 2020 13% -0.09% -0.68% 30 Sep 2020
Q2 2020 12% +2% +20% 30 Jun 2020
Q1 2020 13% 31 Mar 2020
Q4 2019 13% 31 Dec 2019
Q3 2019 13% 30 Sep 2019
Q2 2019 10% 30 Jun 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.